Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Want to see APVO full AI Analyst Report?
Top Page
Aptevo Therapeutics
(NASDAQ:APVO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▲(637.70% Upside)
Action:Reiterated
Date:05/28/26
The score is primarily weighed down by weak financial performance (no meaningful revenue and significant ongoing cash burn), which increases financing/dilution risk. Technicals are neutral and do not offset fundamentals, while corporate events provide some upside from encouraging early clinical results and a new strategic collaboration.
Positive Factors
Clinical efficacy of lead candidate
Consistently high clinical benefit and remission rates with favorable safety for mipletamig support a durable competitive edge in frontline AML. These data increase the likelihood of advancing to pivotal studies, enhance regulatory and partner interest, and materially de-risk the program versus early-stage peers.
Negative Factors
No meaningful revenue and persistent losses
Sustained operating losses and effectively zero product revenue mean the company must rely on external financing or partnerships to fund development. This structural cash burn elevates dilution risk and constrains strategic flexibility, affecting ability to execute multi-program development over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy of lead candidate
Consistently high clinical benefit and remission rates with favorable safety for mipletamig support a durable competitive edge in frontline AML. These data increase the likelihood of advancing to pivotal studies, enhance regulatory and partner interest, and materially de-risk the program versus early-stage peers.
Read all positive factors
Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.26M
Dividend YieldN/A
Average Volume (3M)11.64M
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue GrowthN/A
EPS Growth99.36%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.47
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Aptevo Therapeutics Business Overview & Revenue Model
Company Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell eng...
How the Company Makes Money
Aptevo primarily generates revenue through collaboration and licensing arrangements tied to its antibody engineering platforms and drug candidates, rather than through product sales (as a clinical-stage company without marketed drugs). Under these...
Aptevo Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.11M | 12.29M |
| Gross Profit | -116.00K | -240.00K | -352.00K | 0.00 | 3.11M | 12.29M |
| EBITDA | -26.36M | -26.07M | -23.78M | -28.31M | -27.74M | -20.26M |
| Net Income | -26.26M | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
Balance Sheet | ||||||
| Total Assets | 19.90M | 27.19M | 15.59M | 24.84M | 34.22M | 56.60M |
| Cash, Cash Equivalents and Short-Term Investments | 14.53M | 21.62M | 8.71M | 16.90M | 22.64M | 45.04M |
| Total Debt | 4.42M | 4.63M | 4.63M | 5.40M | 9.54M | 16.71M |
| Total Liabilities | 8.29M | 9.81M | 10.84M | 12.62M | 16.24M | 55.38M |
| Stockholders Equity | 11.61M | 17.38M | 4.75M | 12.22M | 17.97M | 1.22M |
Cash Flow | ||||||
| Free Cash Flow | -26.98M | -25.59M | -23.79M | -11.73M | -21.05M | -22.39M |
| Operating Cash Flow | -26.98M | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.00K | -713.00K |
| Financing Cash Flow | 39.37M | 38.50M | 15.60M | 6.00M | -2.62M | 26.16M |
Aptevo Therapeutics Technical Analysis
Positive
0.61
Price Trends
4.80
Positive
5.83
Negative
15.30
Negative
Market Momentum
0.03
Negative
53.79
Neutral
62.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Positive. The current price of 0.61 is below the 20-day moving average (MA) of 4.87, below the 50-day MA of 4.80, and below the 200-day MA of 15.30, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 62.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APVO.
Aptevo Therapeutics Risk Analysis
Aptevo Therapeutics disclosed 57 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptevo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $25.14M | -2.41 | -112.05% | ― | ― | 94.17% | |
46 Neutral | $31.69M | -1.86 | -101.90% | ― | -83.00% | 19.02% | |
46 Neutral | $61.00M | -5.60 | -82.34% | ― | ― | 16.07% | |
44 Neutral | $6.26M | -0.21 | -389.34% | ― | ― | 99.36% | |
44 Neutral | $13.13M | -3.41 | ― | ― | ― | 80.65% |
* Healthcare Sector Average
APVO
Aptevo Therapeutics
4.72
-84.38
-94.70%
LSTA
Lisata Therapeutics
3.35
0.66
24.54%
MBRX
Moleculin Biotech
2.40
-14.35
-85.67%
EDSA
Edesa Biotech
5.46
3.63
198.36%
ALLR
Allarity Therapeutics
1.61
0.76
89.41%
Aptevo Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave
Positive
May 27, 2026
On May 25, 2026, Aptevo Research and Development LLC, a subsidiary of Aptevo Therapeutics, and Niowave entered into a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs combining Aptevo’s multispecific...
Business Operations and Strategy
Aptevo Highlights Strong Phase 1b AML Trial Results
Positive
May 6, 2026
On May 6, 2026, Aptevo reported new data from its RAINIER Phase 1b frontline acute myeloid leukemia trial showing that mipletamig, combined with venetoclax and azacitidine, achieved an 87% clinical benefit rate and 81% remission in 31 evaluable pa...
Business Operations and StrategyProduct-Related Announcements
Aptevo Reports Promising Interim Data for AML Therapy
Positive
Mar 11, 2026
On March 10, 2026, Aptevo Therapeutics reported new interim data from two trials of its lead candidate mipletamig, used in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.